Synovio Therapeutics
Drug Candidate for Osteoarthritis Therapy
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in January 2025 by adi Sagiv Meister, Synovio Therapeutics operates with 1–10 employees. The company has secured funding across one round from one investor, with a significant grant received from the Israel Innovation Authority in September 2025.
Business overview
Synovio Therapeutics is a Health Tech & Life Sciences company focused on the development of novel drug candidates. The company's core technology involves Fenchone 1D, a specific agonist to the CB2 receptor, which is being developed as a treatment for Osteoarthritis. Operating within the Pharma & Medical Biotechnology sector, Synovio Therapeutics targets the Life Sciences and Pharmaceuticals markets with its drug discovery and development efforts.
Log in to access full profile ›Company Intelligence Q&A
- What is Synovio Therapeutics' primary focus?
- Synovio Therapeutics is focused on developing a novel small molecule, Fenchone 1D, as a drug candidate for Osteoarthritis therapy.
- When was Synovio Therapeutics founded?
- Synovio Therapeutics was founded in January 2025.
- Who is the founder of Synovio Therapeutics?
- adi Sagiv Meister is the founder of Synovio Therapeutics.
- Has Synovio Therapeutics received any funding?
- In September 2025, Synovio Therapeutics secured a grant from the Israel Innovation Authority.
- What stage of development is Synovio Therapeutics' product in?
- Synovio Therapeutics' product, Fenchone 1D, is currently in the R&D stage, as of September 2025, following a grant from the Israel Innovation Authority.